Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)
Key facts
- Who runs it
- University of California, Davis
- Where
- Sacramento, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- Jul 2024
- Ended
- May 2026
- Type of study
- Interventional
- Treatments tested
- Aminolevulinic Acid
- Record updated
- 15 August 2024
- Why it stopped
- PI choice.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Histological confirmation of any subtype of primary Grades 2 or 3 soft tissue sarcomas (STS), per biopsy evaluation by a pathologist, according to Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
- Treatment decision includes planned surgical resection of STS
- Age ≥18 years at time of consent
- ECOG Performance Status 0 - 1 (see Appendix)
- Hematology and blood chemistry parameters defined by:; Leukocytes ≥ 3 × 109/L; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L, transfusions may be used to raise platelets to ≥ 100 × 109/L (no washout required); Hemoglobin ≥ 9 g/dL, transfusions may be used to raise Hgb to ≥ 9 g/dL (no washout required); Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); Aspartate transaminase (AST) / alanine transaminase (ALT) ≤ 2.5 × institutional ULN; Creatinine within normal institutional limits OR creatinine clearance ≥ 30 mL/min/1.73 m2 for patients with creatinine above institutional ULN
- Participants of reproductive potential must agree to using adequate contraception (e.g., hormonal or barrier method of birth control; abstinence, an intrauterine device) for the duration of study participation (including dosing interruptions) and up to 42 days after end of study intervention; or be surgically sterilized (e.g., hysterectomy, tubal ligation, or vasectomy)
- Ability to swallow study agent
- Ability to understand and willingness to sign an informed consent form
- Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study
Who cannot take part
- Uncontrolled, known concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness
- Patient has had chemotherapy, tumor resection, or radiation treatment ≤ 21 days prior to surgery
- Planned use of other potentially phototoxic substances (e.g., St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones and tetracyclines), and topical preparations containing aminolevulinic acid (5-ALA) for 24 hours during the perioperative period (defined as 24 hours prior to surgery to up to 24 hours post surgery)
- Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial
- Acute/chronic forms of porphyria
- Simultaneous participation in another clinical trial ≤ 21 days of enrollment or during the duration of the study period
- Pregnant or planning to become pregnant during study participation or breastfeeding
Where in United States
- University of California Davis Comprehensive Cancer CenterSacramento, United States
About the trial
What the trial wants to find out
This will be a prospective pilot study that will evaluate 20 patients who were diagnosed with FNCLCC Grade 2 or 3 soft tissue sarcomas and will undergo surgical resection. Based upon the FDA label, successful protocols used for intraoperative fluorescence-guided visualization for glioma resections, and on drug company current dosing recommendation for this study, patients will be administered 20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgery. The use of 5-ALA fluorescence will be relevant for evaluating the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.
The group in the trial
- Aminolevulinic acid (5-ALA)Treatment being tested
20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgical resection. 5-ALA fluorescence will be used to evaluate the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.
Treatment: Aminolevulinic Acid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 August 2024